Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

Published:2020-10 Issue:4 Volume:42 Page:373-375
ISSN:2531-1379
Container-title:Hematology, Transfusion and Cell Therapy
language:en
Short-container-title:Hematology, Transfusion and Cell Therapy

Author:

Centrone Renato^ORCID,Bellesso Marcelo,Bonito Debora,Dias Daniela,Santucci Rodrigo,Aranha Milton,Alves Adelson

Publisher

Elsevier BV

Subject

Hematology,Immunology and Allergy

Reference15 articles.

1. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

2. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;J Clin Oncol,2009

3. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia;O’Brien;J Natl Compr Canc Netw,2009

4. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial;Kantarjian;Lancet Oncol,2011

5. When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia;Laneuville;Curr Treat Options Oncol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP